Should You “Buy The Dip” In This Biotech With A Revolutionary Cancer Treatment?

The biotech stock that’s the focus of today’s article recently dipped after reporting clinical trial results for its revolutionary cancer treatment “that were positive but perhaps not positive enough to outrun the competition.” So could it represent a good “buy the dip” opportunity? The author outlines the reasons to consider buying this stock, as well as some reasons to exercise caution. For more, CLICK HERE.